Last reviewed · How we verify
AVZIVI (BEVACIZUMAB-TNJN)
AVZIVI (generic name: BEVACIZUMAB-TNJN) is a drug developed by BIO-THERA SOLUTIONS LTD. It is currently FDA-approved.
AVZIVI is an antibody that targets vascular endothelial growth factor A, and it is being studied in clinical trials for various ovarian cancer indications, including Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, and Ovarian Carcinoma. AVZIVI works as a vascular endothelial growth factor A inhibitor.
At a glance
| Generic name | BEVACIZUMAB-TNJN |
|---|---|
| Sponsor | BIO-THERA SOLUTIONS LTD |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Epistaxis
- Headache
- Hypertension
- Rhinitis
- Proteinuria
- Taste alteration
- Dry skin
- Hemorrhage
- Lacrimation disorder
- Back pain
- Exfoliative dermatitis
- Leukopenia
Serious adverse events
- Deep vein thrombosis
- Hypertension
- Leukopenia
- Neutropenia
- Diarrhea
- Intra-abdominal thrombosis
- Syncope
- Asthenia
- Abdominal pain
- Pain
Key clinical trials
- Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positiv (Phase 3)
- Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients (Phase 3)
- A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage I (Phase 2)
- A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma (Phase 2)
- A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreducti (Phase 3)
- A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer (Phase 2)
- A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors (Phase 1)
- A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as In (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AVZIVI CI brief — competitive landscape report
- AVZIVI updates RSS · CI watch RSS
- BIO-THERA SOLUTIONS LTD portfolio CI
Frequently asked questions about AVZIVI
What is AVZIVI?
Who makes AVZIVI?
What is the generic name of AVZIVI?
What development phase is AVZIVI in?
What are the side effects of AVZIVI?
Related
- Manufacturer: BIO-THERA SOLUTIONS LTD — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing